Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05660850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2023
Completion date
October 20, 2024
Enrollment
49 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic refractory cough (crc) with non-atopic asthma, crc with atopic asthma, crc with chronic obstructive pulmonary disease, crc with chronic obstructive pulmonary disease with chronic bronchitis, unexplained chronic cough